How many doses of hepatitis B immunoglobulin (HBIG) are required?

Hepatitis B Human Immunoglobulin (HBIG) is primarily used for the prevention of hepatitis B. It is indicated for: infants born to mothers who are hepatitis B surface antigen (HBsAg)-positive; individuals with accidental exposure to hepatitis B virus (HBV); and persons in close contact with hepatitis B patients or HBV carriers. So, how many doses of hepatitis B immunoglobulin are required? Below, we provide a detailed explanation.

How Many Doses of Hepatitis B Immunoglobulin Are Required?

The hepatitis B vaccine is typically administered in three doses, following a 0–1–6 schedule: “0” refers to the time of the first dose; “1” indicates the second dose given one month after the first; and “6” denotes the third dose administered six months after the first. Vaccination can be performed at local community health centers or disease control and prevention institutions. However, hepatitis B vaccination does not confer lifelong immunity. Post-vaccination serologic testing is essential to assess immune response and quantify anti-HBs antibody titers. If the titer falls below the protective threshold of 10 mIU/mL, a booster dose is recommended to maintain an effective anti-HBs antibody level and ensure reliable protection against HBV infection. We recommend checking anti-HBs antibody titers one month after completing the three-dose series to determine whether a booster is needed. For newborns, HBIG and the first dose of hepatitis B vaccine should be administered within 24 hours of birth—ideally as soon as possible—and a single dose of HBIG is currently recommended.

Additional Information: Potential Side Effects of Hepatitis B Immunoglobulin

1. Allergic Reactions

Administration of immunoglobulin may trigger allergic reactions in susceptible individuals—particularly those with underlying medical conditions. Such reactions occur when antigens in the body interact chemically with the administered immunoglobulin, potentially causing symptoms including pruritus, swelling, and significant cutaneous manifestations. Therefore, a pre-administration skin test is strongly advised to assess individual suitability for immunoglobulin therapy.

2. Immune Dysregulation

Immunoglobulin administration may modulate endogenous antibody production and suppress immunoglobulin synthesis, thereby disrupting normal immune homeostasis. This may predispose recipients to immune dysfunction or even graft-versus-host-like reactions. Comprehensive immunologic assessment prior to administration is therefore critical to minimize the risk of adverse immune responses.

3. Increased Blood Viscosity

Blood composition is normally tightly regulated; however, immunoglobulin infusion may elevate plasma protein concentration, leading to increased blood viscosity. Elevated viscosity heightens the risk of thrombotic events and other systemic complications.

The above outlines the dosing regimen for hepatitis B immunoglobulin. We hope this information proves helpful.